CAS: 870964-67-3; 2-(4-((S)-3-(((R)-1-(Naphthalen-1-yl)Ethyl)Amino)Pyrrolidin-1-yl)Phenyl)Acetic Acid

该化合物是一种复杂的有机化合物,其特点是多功能结构.该物质具有凝固氯化萘的特性,有助于其疏水性,并形成一个可能影响其生物活动和与受体互动的阳性环.乙酸功能组的存在表明,有可能发生离子相互作用,提高极溶剂的溶性.由于有手动中心,该化合物有可能表现出特定的立体化学特性,从而对其药用特性产生重大影响.这些化合物经常因其潜在的治疗用途,特别是在药用化学和药物开发领域,而受到调查.功能组和立体化学组的复杂安排,也可能在确定化合物与生物目标的结合性和选择性方面发挥关键作用.

结构式图片

欧盟法规

C&L通报

上下游产品

N-(Tert-Butoxycarbonyl)-3-(1-(R)-α-Naphthylethyl)-Aminopyrrolidine 870859-04-4

合成工艺路线路线简述

  • 14062-25-0 + 870966-25-9 + 1666124-27-1 = 870964-67-3
    反应条件:1.1 Reagents: Cesium Carbonate Catalysts: Palladium Diacetate,X-Phos Solvents: Toluene1.2 Reagents: Hydrochloric Acid Solvents: Water2.1 Reagents: Sodium Hydroxide Solvents: Ethanol2.2 Reagents: Citric Acid
    标题:Isolation,Synthesis,Identification Of New Process-Related Impurities In Evocalcet
    作者:Yan,Hongyi; Et Al
    参考文献:Journal Of Pharmaceutical And Biomedical Analysis 日期:2022 卷标:214]

    1039631-63-4 = 870964-67-3
    反应条件:1.1 Reagents: Acetyl Chloride Solvents: Isopropanol2.1 Reagents: Cesium Carbonate Catalysts: Palladium Diacetate,X-Phos Solvents: Toluene2.2 Reagents: Hydrochloric Acid Solvents: Water3.1 Reagents: Sodium Hydroxide Solvents: Ethanol3.2 Reagents: Citric Acid
    标题:Isolation,Synthesis,Identification Of New Process-Related Impurities In Evocalcet
    作者:Yan,Hongyi; Et Al
    参考文献:Journal Of Pharmaceutical And Biomedical Analysis 日期:2022 卷标:214]

    1092366-92-1 + 3886-70-2 = 870964-67-3
    反应条件:1.1 Reagents: Tripotassium Phosphate Solvents: Acetonitrile2.1 Reagents: Acetyl Chloride Solvents: Isopropanol3.1 Reagents: Cesium Carbonate Catalysts: Palladium Diacetate,X-Phos Solvents: Toluene3.2 Reagents: Hydrochloric Acid Solvents: Water4.1 Reagents: Sodium Hydroxide Solvents: Ethanol4.2 Reagents: Citric Acid
    标题:Isolation,Synthesis,Identification Of New Process-Related Impurities In Evocalcet
    作者:Yan,Hongyi; Et Al
    参考文献:Journal Of Pharmaceutical And Biomedical Analysis 日期:2022 卷标:214]

    3886-70-2 + 103057-44-9 = 870964-67-3
    反应条件:1.1 Reagents: Trifluoromethanesulfonic Acid,Diisopropylethylamine Solvents: Dichloromethane; -20 °C; 15 Min,-20 °C1.2 Solvents: Dichloromethane; -20 °C; Overnight,Rt1.3 Reagents: Sodium Bicarbonate Solvents: Water; Rt2.1 Reagents: Triethylamine Solvents: Dichloromethane; -20 °C; 1 H,5 °C2.2 Solvents: Water2.3 Reagents: Diisopropylethylamine Solvents: Tert-Butanol; Overnight,70 °C3.1 Reagents: Hydrochloric Acid Solvents: Chloroform,1,4-Dioxane; Rt; Overnight,Rt4.1 Reagents: Sodium Tert-Butoxide Catalysts: Tris(Dibenzylideneacetone)Dipalladium,2-(Di-Tert-Butylphosphino)Biphenyl Solvents: Toluene; Overnight,Rt5.1 Reagents: Sodium Hydroxide Solvents: Ethanol,Water; Overnight,Rt5.2 Reagents: Citric Acid Solvents: Chloroform,Water; Ph 7,Cooled5.3 Solvents: Ethanol; 30 Min,50 - 60 °C; 20 Min,Reflux; Reflux -> Rt; Overnight,Rt
    标题:Discovery Of Evocalcet,A Next-Generation Calcium-Sensing Receptor Agonist For The Treatment Of Hyperparathyroidism
    作者:Miyazaki,Hiroshi; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2018 卷标:28(11) 页码:2055-2060]

    1666124-29-3 = 870964-67-3
    反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Ethanol1.2 Reagents: Citric Acid
    标题:Isolation,Synthesis,Identification Of New Process-Related Impurities In Evocalcet
    作者:Yan,Hongyi; Et Al
    参考文献:Journal Of Pharmaceutical And Biomedical Analysis 日期:2022 卷标:214]

    1666124-30-6 = 870964-67-3
    反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Ethanol,Water; Overnight,Rt1.2 Reagents: Citric Acid Solvents: Chloroform,Water; Ph 7,Cooled1.3 Solvents: Ethanol; 30 Min,50 - 60 °C; 20 Min,Reflux; Reflux -> Rt; Overnight,Rt
    标题:Discovery Of Evocalcet,A Next-Generation Calcium-Sensing Receptor Agonist For The Treatment Of Hyperparathyroidism
    作者:Miyazaki,Hiroshi; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2018 卷标:28(11) 页码:2055-2060]

    14062-25-0 + 870858-86-9 = 870964-67-3
    反应条件:1.1 Reagents: Sodium Tert-Butoxide Catalysts: Tris(Dibenzylideneacetone)Dipalladium,2-(Di-Tert-Butylphosphino)Biphenyl Solvents: Toluene; Overnight,Rt2.1 Reagents: Sodium Hydroxide Solvents: Ethanol,Water; Overnight,Rt2.2 Reagents: Citric Acid Solvents: Chloroform,Water; Ph 7,Cooled2.3 Solvents: Ethanol; 30 Min,50 - 60 °C; 20 Min,Reflux; Reflux -> Rt; Overnight,Rt
    标题:Discovery Of Evocalcet,A Next-Generation Calcium-Sensing Receptor Agonist For The Treatment Of Hyperparathyroidism
    作者:Miyazaki,Hiroshi; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2018 卷标:28(11) 页码:2055-2060]

    870858-88-1 = 870964-67-3
    反应条件:1.1 Reagents: Hydrochloric Acid Solvents: Chloroform,1,4-Dioxane; Rt; Overnight,Rt2.1 Reagents: Sodium Tert-Butoxide Catalysts: Tris(Dibenzylideneacetone)Dipalladium,2-(Di-Tert-Butylphosphino)Biphenyl Solvents: Toluene; Overnight,Rt3.1 Reagents: Sodium Hydroxide Solvents: Ethanol,Water; Overnight,Rt3.2 Reagents: Citric Acid Solvents: Chloroform,Water; Ph 7,Cooled3.3 Solvents: Ethanol; 30 Min,50 - 60 °C; 20 Min,Reflux; Reflux -> Rt; Overnight,Rt
    标题:Discovery Of Evocalcet,A Next-Generation Calcium-Sensing Receptor Agonist For The Treatment Of Hyperparathyroidism
    作者:Miyazaki,Hiroshi; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2018 卷标:28(11) 页码:2055-2060]

    870859-04-4 = 870964-67-3
    反应条件:1.1 Reagents: Triethylamine Solvents: Dichloromethane; -20 °C; 1 H,5 °C1.2 Solvents: Water1.3 Reagents: Diisopropylethylamine Solvents: Tert-Butanol; Overnight,70 °C2.1 Reagents: Hydrochloric Acid Solvents: Chloroform,1,4-Dioxane; Rt; Overnight,Rt3.1 Reagents: Sodium Tert-Butoxide Catalysts: Tris(Dibenzylideneacetone)Dipalladium,2-(Di-Tert-Butylphosphino)Biphenyl Solvents: Toluene; Overnight,Rt4.1 Reagents: Sodium Hydroxide Solvents: Ethanol,Water; Overnight,Rt4.2 Reagents: Citric Acid Solvents: Chloroform,Water; Ph 7,Cooled4.3 Solvents: Ethanol; 30 Min,50 - 60 °C; 20 Min,Reflux; Reflux -> Rt; Overnight,Rt
    标题:Discovery Of Evocalcet,A Next-Generation Calcium-Sensing Receptor Agonist For The Treatment Of Hyperparathyroidism
    作者:Miyazaki,Hiroshi; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2018 卷标:28(11) 页码:2055-2060]

    109431-87-0 = 870964-67-3
    反应条件:1.1 Reagents: Triethylamine,Trimethylammonium Chloride Solvents: Dichloromethane2.1 Reagents: Tripotassium Phosphate Solvents: Acetonitrile3.1 Reagents: Acetyl Chloride Solvents: Isopropanol4.1 Reagents: Cesium Carbonate Catalysts: Palladium Diacetate,X-Phos Solvents: Toluene4.2 Reagents: Hydrochloric Acid Solvents: Water5.1 Reagents: Sodium Hydroxide Solvents: Ethanol5.2 Reagents: Citric Acid
    标题:Isolation,Synthesis,Identification Of New Process-Related Impurities In Evocalcet
    作者:Yan,Hongyi; Et Al
    参考文献:Journal Of Pharmaceutical And Biomedical Analysis 日期:2022 卷标:214
(R)-1-(1-萘基)乙胺置于盐酸,Tris-(Dibenzylideneacetone)Dipalladium(0),三氟甲磺酸,N,N-二异丙基乙胺,Sodium Hydroxide,2-(二叔丁基膦)联苯,Sodium T-Butanolate体系中,用 1,4-二氧六环,乙醇,二氯甲烷,氯仿,水,甲苯 作为反应溶剂,化学反应 1.25H,反应生成 伊万卡赛
参考文献:发现用于治疗甲状旁腺功能亢进症的下一代钙敏感受体激动剂evocalcet
标题:发现用于治疗甲状旁腺功能亢进症的下一代钙敏感受体激动剂evocalcet
摘要:钙敏感受体(casr)在检测细胞外钙离子和调节甲状旁腺细胞分泌的甲状旁腺激素中起重要作用,并且该受体是治疗甲状旁腺功能亢进症的合适靶标.盐酸西那卡塞是一种代表性的casr激动剂,广泛用于甲状旁腺功能亢进症.但是,它对临床使用存在一些问题,例如恶心/呕吐和对cyp2D6的强抑制作用.我们试图改善cinacalcet的这些问题,从而使新药物成为可取的casr激动剂.通过cinacalcet的优化可鉴定出吡咯烷化合物,并成功地导致了evocalcet作为口服变构casr激动剂的发现.evocalcet具有高度有利的特性,例如casr激动活性和非常好的dmpk特性,
DOI:10.1016/j.Bmcl.2018.04.055

海关参考信息

专利信息


专利号:CN-118185893-A
优先权日:2024-03-27
标 题:Imine reductase mutants and their application in the synthesis of ivankaser chiral intermediates

专利号:CN-116693440-A
优先权日:2023-05-18
标 题:A kind of scavenging method of palladium catalyst in Ivankaser intermediate VI synthesis technique
北京迈索化学技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.huafenginfo.com
企业联系电话:010-57862036,65405760👤
📞北京迈索化学技术有限公司 ⚠️参考联系方式
联系人:崔先生
电话:010-57862036,65405760
手机:13366977697
传真:010-57862181
邮箱:sales@mesochem.com
通信地址: 北京市亦庄经济技术开发区荣华中路力宝广场9座23层
邮编: 100176
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:北京市亦庄经济技术开发区荣华中路力宝广场9座23层
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
北京华奉联博科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.huafenginfo.com
电话:010-57862036,65405760👤
📞 北京华奉联博科技有限公司⚠️参考联系方式

电话: 010-57862036,65405760
邮件:sales@mesochem.com
网址: http://www.huafenginfo.com
地址:北京市亦庄经济技术开发区荣华中路力宝广场9座23层
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

北京市亦庄经济技术开发区荣华中路力宝广场9座23层
⚠️ 未注册 · 未认证企业
注册入口 备注: 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别. 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. Ther Apher Dial. 2019 Sep 5;24(3):248–57. doi: 10.1111/1744-9987.13434. Epub ahead of print.
2: Sakai M, Tokunaga S, Kawai M, Murai M, Kobayashi M, Kitayama T, Saeki S, Kawata T. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism. PLoS One. 2020 Apr 28;15(4):e0232428. doi: 10.1371/journal.pone.0232428.
3: Parfrey PS. Evocalcet in the management of secondary hyperparathyroidism in dialysis patients. Kidney Int. 2018 Oct;94(4):661-662. doi: 10.1016/j.kint.2018.06.022. Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018 Oct;94(4):818-825. doi: 10.1016/j.kint.2018.05.013. Epub 2018 Jul 24. Evocalcet Study Group. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. Clin Exp Nephrol. 2019 Feb;23(2):258-267. doi: 10.1007/s10157-018-1635-6. Epub 2018 Aug 29.

合成参考文献


参考文献:10.1016/j.bmcl.2018.04.055
摘要:Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, Kuroda M, Hisada Y, Yanagida T, Yoneda H, Tsukumo Y, Tokunaga S, Kawata T, Ohashi R, Fukuda H, Kojima K, Kannami A, Kifuji T, Sato N, Idei A, Iguchi T, Sakairi T, Moritani Y. Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. Bioorganic & Medicinal Chemistry Letters. 2018 Jun;28(11):2055–60. doi: 10.1016/j.bmcl.2018.04.055.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知